Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 5, 2006, Pages 950-954

  Malincarne, L ^a   Ghebregzabher, M ^a   Moretti, M V ^a   Egidi, A M ^a   Canovari, B ^a   Tavolieri, G ^a   Francisci, D ^a   Cerulli, G ^a   Baldelli, F ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cancellous bone; Cortical bone; Fluoroquinolones; Osteomyelitis

Indexed keywords

MOXIFLOXACIN;

ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CANCELLOUS BONE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL BONE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG DOSE REGIMEN; DRUG PENETRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KNEE ARTHROPLASTY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; OPEN STUDY; PREOPERATIVE CARE; SINGLE DRUG DOSE; TUBERCULOUS OSTEOMYELITIS;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ARTHROPLASTY, REPLACEMENT, KNEE; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEG BONES; MALE; OSTEOMYELITIS; QUINOLINES; TISSUE DISTRIBUTION;

EID: 33645827123     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl091     Document Type: Article

References (34)

1. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004: 364: 369-79.
2. Mader JT, Shirtliff ME, Bergquist SC et al. Antimicrobial treatment of chronic osteomyelitis. Clin Orthop Relat Res 1999; 360: 47-65.
3. Lew DP, Waldvogel FL. Use of fluoroquinolones in osteomyelitis and infected orthopaedic prosthesis. Drugs 1999; 58 Suppl 2: 85-91.
4. Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the fluoroquinolones. Clin Infect Dis 1997; 25: 1327-33.
5. Blondeau JM. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory fluoroquinolones. J Antimicrob Chemother 1999; 43 Suppl B: 1-11.
6. Fass RJ. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother 1997; 41: 1818-24.
7. Hoogkamp-Korstanjie JAA, Roelofs-Willemse J. Comparative in vitro activity of moxifloxacin against Gram positive clinical isolates. J Antimicrob Chemother 2000; 45: 31-9.
8. Malathum K, Singh KV, Murray BE. In vitro activity of moxifloxacin, a new 8-methoxyquinolone against Gram-positive bacteria. Diagn Microbiol Infect Dis 1999; 35: 127-33.
9. Speciale A, Musumeci G, Blandino I et al. Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates. Int J Antimicrob Agents 2002; 19: 111-18.
10. Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of Moxifloxacin. Clin Infect Dis 2001; 32 Suppl 1: 52-61.
11. Lister PD. Pharmacodinamics of Moxifloxacin and Levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodinamic model. Clin Infect Dis; 32 Suppl 1: 33-8.
12. Nawas BA, Shah MP. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1998; 41: 655-8.
13. Schmitz FJ, Hofmann B, Hansen B et al. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MIC and mutations in grl A, grl B, gyr A and gyr B in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998; 41: 481-4.
14. von Eiff C, Peters G. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 1999; 43: 569-73.
15. Gumbo T, Louie A, Deziel MR et al. Selection of moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic model and mathematical modelling. J Infect Dis 2004; 190: 1642-51.
16. Sulochana S, Rahman F, Paramasivan CN. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 2005; 17: 169-73.
17. Brehil D, Jougon J, Djabarouti S et al. Diffusion of oral and intravenous 400 mg once daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J Chemother 2003; 15: 558-62.
18. Dinis PB, Monteiro MC, Martins ML et al. Sinus tissue concentration of moxifloxacin after a single oral dose. Ann Otol Rhinol Laryngol 2004; 113: 142-6.
19. Lubasch A, Keller I, Borner K et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-3.
20. Muller M, Staß H, Brunner M et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345-9.
21. Mader JT, Shirtliff M, Calhoun JH. Staging and staging application osteomyelitis. Clin Infect Dis 1997; 25: 1303-9.
22. Janssens JP, de Haller R. Spinal tuberculosis in a developed country: A review of 26 cases with special emphasis on abscesses and neurological complications. Clin Orthop Relat Res 1990; 257: 67-75.
23. Bernard L, Waldvogel FA. Treatment of osteomyelitis and septic arthritis. In: Hooper DC, Rubinstein E, eds. Quinolone Antimicrobial Agents, 3rd edn. Washington: ASM Press, 2003; 251-8.
24. Baum Hv, Bottcher S, Abel R et al. Tissue and serum concentrations of levofloxacin in orthopaedic patients. Int J Antimicrob Agents 2001; 18: 335-40.
25. Etesse-carsenti H, Garaffo R, Giaume F et al. Kinetics of pefloxacin diffusion in human bone tissue following a single infusion of 800 mg. Evaluation of an extraction technic using chlorophorm. Pathol Biol 1988; 36: 715-8.
26. Hofmann GO, Kees F. Penetration of levofloxacin into human knee joint. Antiinf Drugs Chemother 2000; 17: 77.
27. Meissner A, Borner K, Koeppe P. Concentration of ofloxacin in human bone and cartilage. J Antimicrob Chemother 1990; 26: D69-74.
28. Stass H, Dahloff A, Kubitza D et al. Pharmacokinetics, safety and tolerability of ascending doses of moxifloxacin, a new 8-methoxyquinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-5.
29. Wise R, Andrews JM, Marshall G et al. Pharmacokinetics and inflammatory fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999: 43: 1508-11.
30. Keith AR, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21: 233S-52S.
31. Pascual A, Garcia I, Ballesta S et al. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob Agents Chemother 1999; 43: 12-15.
32. Woodcock JM, Andrews F, Andrews FJ et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-6.
33. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae and Other Aerobic Actinomycetes: Approved Standards M24-A. NCCLS, Wayne, PA, USA, 2003.
34. Noel GJ, Natarajan J, Chien S et al. Effects of the three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003; 73: 292-303.